ABCL Stock Recent News
ABCL LATEST HEADLINES
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chairperson Tryn T.
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.13 per share a year ago.
ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025.
ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 6.19%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.